Scrotal Erythema Associated with Sorafenib Therapy in a Patient with Hepatocellular Carcinoma / 대한피부과학회지
Korean Journal of Dermatology
; : 136-140, 2016.
Artículo
en Coreano
| WPRIM (Pacífico Occidental)
| ID: wpr-73822
Biblioteca responsable:
WPRO
ABSTRACT
Sorafenib is an oral, multi-targeted tyrosine kinase inhibitor with anti-angiogenic and anti-proliferative activity. It is approved for the treatment of unresectable hepatocellular and advanced renal carcinomas. Cutaneous toxicity is relatively common in patients receiving sorafenib. The most frequent cutaneous side effect is the hand-foot syndrome. Other adverse skin reactions include facial erythema, acral erythema, erythema multiforme, subungual splinter hemorrhage, stomatitis, and alopecia. In Korea, two cases of scrotal and perianal dermatitis after sorafenib therapy were reported. We report a 54-year-old male patient with a 2-week history of scrotal eczema who had been treated for chronic hepatitis type B, liver cirrhosis, and hepatocellular carcinoma. After 2 weeks of oral sorafenib (800 mg/day) administration, thick, scaly patches appeared on his scrotum. A skin biopsy specimen from these lesions revealed superficial dermal perivascular lymphocytic and neutrophilic infiltration, and dilatation of the lymphatics in the superficial dermis. The lesions improved after treatment with a topical and systemic steroid for 2 weeks. Herein, we report a rare case of scrotal erythema associated with sorafenib.
Texto completo:
Disponible
Base de datos:
WPRIM (Pacífico Occidental)
Asunto principal:
Escroto
/
Piel
/
Estomatitis
/
Biopsia
/
Proteínas Tirosina Quinasas
/
Eritema Multiforme
/
Carcinoma Hepatocelular
/
Dermis
/
Dermatitis
/
Dilatación
Límite:
Humanos
/
Masculino
País/Región como asunto:
Asia
Idioma:
Coreano
Revista:
Korean Journal of Dermatology
Año:
2016
Tipo del documento:
Artículo